肝脏 ›› 2026, Vol. 31 ›› Issue (1): 92-95.

• 其他肝病 • 上一篇    下一篇

30例特发性非硬化性门静脉高压症患者临床病理特征分析

甘雅婷, 何正秀, 庄剑波   

  1. 215000 苏州 苏州高新区人民医院消化内科(甘雅婷,庄剑波);224200 东台 东台市人民医院消化内科(何正秀)
  • 收稿日期:2025-07-09 出版日期:2026-01-31 发布日期:2026-03-30
  • 通讯作者: 庄剑波,Eamil:1648520487@qq.com
  • 基金资助:
    江苏省卫生健康委科研项目(ZD2022052)

Clinicopathologic characterization of 30 patients with idiopathic nonsclerotic portal hypertension

GAN Ya-ting1, HE Zheng-xiu2, ZHUANG Jian-bo1   

  1. 1. Department of Gastroenterology, the People′s Hospital of SND,Suzhou 215000,China;
    2. Department of Gastroenterology, Dongtai People′s Hospital, Dongtai 224200,China
  • Received:2025-07-09 Online:2026-01-31 Published:2026-03-30
  • Contact: ZHUANG Jian-bo, Eamil:1648520487@qq.com

摘要: 目的 分析特发性非硬化性门静脉高压症患者临床病理特征。方法 纳入2019年2月至2022年2月在我院收治并经病理确诊为特发性非硬化性门静脉高压症患者30例,作为观察组,其中男性11例,女性19例,平均年龄为(59.5±4.1)岁,另选择同期体检确诊为乙型肝炎肝硬化门静脉高压症患者30例作为对照组,其中男性20例,女性10例,平均年龄为(59.4±4.2)岁。比较两组临床特征、观察组病理特征和两组临床评分。结果 观察组的女性占比、首发症状为消化道出血、腹部不适、CT检查为脾大、并发症为上消化道出血、食管静脉曲张的占比分别为63.3%、30%、26.7%、30%、33.3%、20%,分别高于对照组[33.3%、6.7%、6.7%、6.7%、10%、3.3%];肝脾肿大占比、ALT、AST、TBil、肌酐水平、PLT、WBC、中性粒细胞、PT分别为13.3%、(41.5±5.6)U/L、(46.2±8.3)U/L、(19.25±2.4)μmol/L、(122.3±12.3)μmol/L、(57.6±21.6)×109/L、(2.6±1.7)×109/L、(22.8±4.7)×109/L、(15.3±2.5)s,分别低于对照组[46.7%、(72.3±6.8)U/L、(75.9±5.6)U/L、(32.6±8.5)μmol/L、(152.3±25.6)μmol/L、(65.3±31.2)×109/L、(5.6±2.1)×109/L、(36.5±8.9)×109/L、(18.2±3.1)s],D-二聚体、PTA、肾小球滤过率分别为(0.9±0.4)、(71.2±3.2)%、(109.8±23.2)mL·min-1,分别高于对照组[(0.5±0.1)、(62.3±2.5)%、(101.2±18.6)mL·min-1](P<0.05)。观察组主要改变为汇管区基质纤维化、门静脉小分支纤维性闭塞、汇管区末端门静脉小分支扩张增粗。邻近肝实质的肝窦不同程度扩张,较大的门静脉壁增厚,其中平滑肌增生伴有纤维化,甚至发生门静脉硬化并伴有血栓形成。观察组的Child-Pugh评分、终末期肝病模型评分、APRI评分、肝硬度分别为(6.1±0.8)分、(10.1±0.5)分、(0.7±0.2)分、(0.8±0.2)kPa,分别低于对照组[(8.2±0.9)分、(16.3±2.5)分、(2.5±0.3)分、(12.6±0.5)kPa],CD34免疫染色阳性占比为90%,高于对照组的40%(P<0.05)。结论 特发性非硬化性门静脉高压病因复杂,临床上相对少见,门静脉高压相关并发症比例较高,尤其是消化道出血。对于门静脉高压严重但肝功能损害轻微、肝脏储备功能良好且肝硬度值较低的患者,应强烈怀疑特发性非硬化性门静脉高压,并结合临床、实验室、影像学和病理学表现进行诊断。

关键词: 特发性, 非硬化性门静脉高压症, 临床, 病理, 特征

Abstract: Objective Analysis of clinicopathologic features in patients with idiopathic non-cirrhotic portal hypertension. Methods 30 cases of patients admitted to our hospital and diagnosed as idiopathic non-cirrhotic portal hypertension by pathology between February 2019 and February 2022 were selected as the observation group, with 11 males and 19 females, and the average age was (59.5±4.1) years old, and another 30 cases of patients diagnosed as hepatitis B-related cirrhotic portal hypertension by physical examination during the same period were selected as the control group, with 20 males and 10 females. The average age was (59.4±4.2) years old, comparing the clinical features of the two groups, the pathological features of the observation group and the clinical scores of the two groups. Results In the observation group, the percentage of females, the percentage of patients whose first symptom was gastrointestinal bleeding, abdominal discomfort, splenomegaly on CT examination, complications of upper gastrointestinal bleeding, and esophageal varices were 63.3%, 30%, 26.7%, 30%, 33.3%, and 20%, which were higher than those in the control group [33.3%, 6.7%, 6.7%, 6.7%, 10%, and 3.3%], respectively; and the percentage of hepatic The percentage of splenomegaly, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine level, platelet count, leukocyte count, neutrophil count, and prothrombin time were 13.3%, (41.5±5.6) U/L, (46.2±8.3) U/L, (19.25±2.4) μmol/L, (122.3±12.3) μmol/L, respectively, (57.6±21.6) × 109/L, (2.6±1.7) × 109/L, (22.8±4.7) × 109/L, and (15.3±2.5) s, respectively, which were lower than those in the control group [46.7%, (72.3±6.8) U/L, (75.9±5.6) U/L, (32.6±8.5) μmol/L, (152.3± 25.6) μmol/L, (65.3±31.2) × 109/L, (5.6±2.1) × 109/L, (36.5±8.9) × 109/L, and (18.2±3.1) s], and D-dimer, prothrombin activity, and glomerular filtration rate were (0.9±0.4), (71.2±3.2)%, (109.8± 23.2) mL·min-1, which were higher than those in the control group [(0.5±0.1), (62.3±2.5)%, (101.2±18.6) mL·min-1], respectively, and the differences were statistically significant (P<0.05). The main changes of observation group were stromal fibrosis in the portal tract, fibrous occlusion of the small branches of the portal vein, and dilatation and thickening of the small branches of the portal vein at the end of the confluent area. The hepatic sinusoids adjacent to the hepatic parenchyma are dilated to varying degrees, and the walls of the larger portal veins are thickened, in which smooth muscle hyperplasia is accompanied by fibrosis, and even portal vein sclerosis with thrombosis occurs. Some patients have prolonged disease, incomplete fibrous septum, and even nodular regenerative hyperplasia. The Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, APRI score, and liver stiffness of the observation group were (6.1±0.8), (10.1±0.5), (0.7±0.2), (0.8±0.2) kPa, which were lower than those of the control group [(8.2±0.9), (16.3±2.5), respectively, (2.5±0.3) points, (12.6±0.5) kPa], and the percentage of positive CD34 immunostaining was 90%, which was higher than 40% in the control group, and the difference was statistically significant (P<0.05). Conclusion Idiopathic non-cirrhotic portal hypertension has a complex etiology and is relatively rare clinically, with a high percentage of complications related to portal hypertension, especially gastrointestinal bleeding. In patients with severe portal hypertension but mild hepatic impairment, good hepatic reserve function, and low liver stiffness, the diagnosis of idiopathic non-cirrhotic portal hypertension should be strongly suspected and made in conjunction with clinical, laboratory, imaging, and pathological manifestations.

Key words: Idiopathic, Non-sclerotic portal hypertension, Clinical, Pathological, Features